1
Your Study Profile
Drag each slider to match your trial. Savings recalculate instantly.
Affects amendment costs, deviation rates and day-of-delay value
10
Clinical sites in your study
6
On-site monitoring visits per site per year
24
Total trial duration in months
80
Total enrolled subjects
€260
CRA hourly billable rate
2
Estimated Total Savings
TOTAL ESTIMATED SAVINGS PER TRIAL
€0
across 4 value pillars
0xReturn on
platform cost
platform cost
€0Savings per
site / year
site / year
192Non-compliances
auto-detected
auto-detected
Figures are indicative averages drawn from published benchmarks. They are not a guarantee of savings, and actual results vary by study.
3
Savings by Value Pillar
Four pillars power your total. One is shown in full. Unlock the report for the other three.
🛡️
TMF / ISF Compliance
Menka AI runs 500+ real-time checks, preventing non-compliances from reaching regulators.
€0
saved per trial
Non-compliances detected (est.)-
Avg remediation cost avoided€12,000 each
% requiring action without tool~15%
⏱️
CRA Monitoring Efficiency
Real-time ISF readiness cuts visit prep and auto-generates monitoring reports, saving ~5 hrs per visit.
€0
saved per trial
Total monitoring visits-
Hours saved per visit~5 hrs
Visit cost reduction~28%
📋
Protocol Amendment Prevention
Early deviation detection stops escalation to costly amendments. 76% of trials face at least one.
€0
saved per trial
Amendments prevented (est.)-
Avg amendment cost-
Delay days avoided-
🔍
Inspection Readiness
Continuous readiness eliminates reactive prep sprints and reduces regulatory risk exposure.
€0
saved per trial
Emergency prep cost avoided€60,000
Minor finding risk reduction€10,800
Industry inspection fail rate36%
🔓
1 OF 4 PILLARS SHOWN
Unlock your full report
See the full breakdown of your €0 in estimated savings, across CRA monitoring, amendment prevention and inspection readiness.
🔓 Unlock full report to view the breakdown
Savings Breakdown, Share of Total
🛡️ TMF / ISF Compliance0%
⏱️ CRA Monitoring Efficiency0%
📋 Protocol Amendment Prevention0%
🔍 Inspection Readiness0%
Benchmark Assumptions
Avg monitoring visit duration
18 hours
Industry standard / CRO billing surveys
Hours saved per visit (Menken)
~5 hours
Pre-visit prep + auto-report generation
Protocol deviations, Phase II
75 avg per trial
PMC benchmarking study, 2022
Protocol deviations, Phase III
119 avg per trial
PMC benchmarking study, 2022
Phase II amendment cost
€141,000
Precision for Medicine, 2024
Phase III amendment cost
€535,000
Industry data, 2026
Avoidable amendments
23-45%
Multiple published analyses
Phase III cost per day of delay
€55,716
Tufts CSDD, August 2024
Inspection failure rate (industry)
36%
Florence Healthcare, 2023
Non-compliances detected (Menken)
192 per 10 sites
Menken Trials internal data
Avg remediation cost per finding
€12,000
Conservative: consultant + CAPA time
Inspection prep (reactive, no tool)
€60,000+
Internal + external consultant cost est.
Do these match your numbers? Every study is different. Tell Menka where your numbers run differently, or which benchmark you would like to see, and she will take it from there.
Share your numbers →
🔓 Unlock full report to view the methodology
How Each Pillar Is Calculated
🛡️ TMF / ISF Compliance
Non-compliances x 15% escalation rate x 12K per remediation. Scaled by sites and years.
findings x 0.15 x 12,000⏱️ CRA Monitoring
Sites x visits/yr x years x 5 hrs saved x CRO rate. Covers ISF pre-review and auto-report.
visits x 5 x rate/hr📋 Protocol Amendments
Expected amendments x 30% avoidable x amendment cost + delay days x day-of-delay value.
avg_amendments x 30% x phase_cost🔍 Inspection Readiness
Fixed savings: emergency prep (60K) + minor finding risk reduction (30K x 36%).
60,000 + 10,800 = 70,800Ready to model your specific trial?
Book a 30-minute demo and we will run your actual study profile through Menken's live compliance data. No slide decks, just numbers.
Disclaimer: All figures are conservative estimates based on published industry benchmarks and Menken Trials internal data. Actual savings vary by study complexity, geography, regulatory requirements, and operational factors. This tool is indicative only and does not constitute a financial guarantee. Sources: Tufts CSDD (2024), PMC (2022), Precision for Medicine (2024), Florence Healthcare (2023), CRO billing surveys (2024-2025).
